Emese Zsiros, MD, PhD, FACOG

Articles by Emese Zsiros, MD, PhD, FACOG

Where Does KEYNOTE-B96 Regimen Fit in Pretreated Ovarian Cancer?

February 17th 2026

According to Emese Zsiros, MD, PhD, FACOG, the pembrolizumab regimen yields favorable responses and survival in this PROC population.

Emese Zsiros, MD, PhD, FACOG, spoke about the newly approved pembrolizumab regimen in PD-L1–expressing, pretreated platinum-resistant gynecologic cancers.

How Tolerable is Pembrolizumab/Paclitaxel/Bevacizumab in PROC?

ByEmese Zsiros, MD, PhD, FACOG

February 16th 2026

Emese Zsiros, MD, PhD, FACOG, spoke about the newly approved pembrolizumab regimen in PD-L1–expressing, pretreated platinum-resistant gynecologic cancers.

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC

Yoga Could Alter Cancer-Related Fatigue Levels Across Solid Tumors

109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR

107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)